196 related articles for article (PubMed ID: 35546370)
21. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey.
Yu SF; Chen JF; Chen YC; Lai HM; Ko CH; Chiu WC; Su FM; Hsu CY; Su BY; Wu CH; Cheng TT
Medicine (Baltimore); 2017 Feb; 96(5):e5959. PubMed ID: 28151883
[TBL] [Abstract][Full Text] [Related]
22. [Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis].
Tanaka I
Clin Calcium; 2014 Sep; 24(9):1371-8. PubMed ID: 25177010
[TBL] [Abstract][Full Text] [Related]
23. Effects of Systemic Glucocorticoid Use on Fracture Risk: A Population-Based Study.
Koh JW; Kim J; Cho H; Ha YC; Kim TY; Lee YK; Kim HY; Jang S
Endocrinol Metab (Seoul); 2020 Sep; 35(3):562-570. PubMed ID: 32981298
[TBL] [Abstract][Full Text] [Related]
24. Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?
Lee JH; Cho SK; Han M; Kim D; Bae SC; Sung YK
Korean J Intern Med; 2014 Jul; 29(4):509-15. PubMed ID: 25045299
[TBL] [Abstract][Full Text] [Related]
25. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
[TBL] [Abstract][Full Text] [Related]
26. Glucocorticoid-induced osteoporosis: 2019 concise clinical review.
Adami G; Saag KG
Osteoporos Int; 2019 Jun; 30(6):1145-1156. PubMed ID: 30805679
[TBL] [Abstract][Full Text] [Related]
27. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
Sato M; Ye W; Sugihara T; Isaka Y
BMC Musculoskelet Disord; 2016 Nov; 17(1):489. PubMed ID: 27887655
[TBL] [Abstract][Full Text] [Related]
28. [Assessment of the treatment of glucocorticoid-induced osteoporosis].
Asano S; Suzuki A
Clin Calcium; 2013 Mar; 23(3):401-8. PubMed ID: 23445894
[TBL] [Abstract][Full Text] [Related]
29. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study.
Majumdar SR; Morin SN; Lix LM; Leslie WD
Osteoporos Int; 2013 Sep; 24(9):2493-8. PubMed ID: 23572142
[TBL] [Abstract][Full Text] [Related]
30. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
Bultink IE; Baden M; Lems WF
Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
[TBL] [Abstract][Full Text] [Related]
31. Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan.
Taguchi T; Matsushima H; Kodama S; Okubo N; Ito T; Ludwikowska M; Fukumoto S; Matsumoto T
Expert Opin Pharmacother; 2024 Feb; 25(3):325-334. PubMed ID: 38588537
[TBL] [Abstract][Full Text] [Related]
32. Glucocorticoid-induced osteoporosis: who to treat with what agent?
Rizzoli R; Biver E
Nat Rev Rheumatol; 2015 Feb; 11(2):98-109. PubMed ID: 25385412
[TBL] [Abstract][Full Text] [Related]
33. Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture.
Ochi K; Inoue E; Furuya T; Ikari K; Toyama Y; Taniguchi A; Yamanaka H; Momohara S
Osteoporos Int; 2015 Mar; 26(3):961-8. PubMed ID: 25294026
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care?
Sapkota S; Baig S; Hess T; O'Connell AM; Menk J; Shyne M; Fazeli P; Ensrud K; Shmagel A
Lupus; 2020 Mar; 29(3):263-272. PubMed ID: 31996109
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses.
Amiche MA; Lévesque LE; Gomes T; Adachi JD; Cadarette SM
J Bone Miner Res; 2018 Mar; 33(3):419-429. PubMed ID: 29068496
[TBL] [Abstract][Full Text] [Related]
36. Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.
Laurent MR; Goemaere S; Verroken C; Bergmann P; Body JJ; Bruyère O; Cavalier E; Rozenberg S; Lapauw B; Gielen E
Front Endocrinol (Lausanne); 2022; 13():908727. PubMed ID: 35757436
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis.
Mori Y; Izumiyama T; Baba K; Mori N; Fujii H; Ishii T; Itoi E
J Orthop Surg Res; 2020 Jul; 15(1):290. PubMed ID: 32727595
[TBL] [Abstract][Full Text] [Related]
38. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first.
Lespessailles E; Chapurlat R
Osteoporos Int; 2020 Oct; 31(10):1829-1834. PubMed ID: 32780152
[TBL] [Abstract][Full Text] [Related]
39. Osteoporosis management among chronic glucocorticoid users: a systematic review.
Albaum JM; Youn S; Levesque LE; Gershon AS; Cadarette SM
J Popul Ther Clin Pharmacol; 2014; 21(3):e486-504. PubMed ID: 25527817
[TBL] [Abstract][Full Text] [Related]
40. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
